Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $5.7M | $9.3M | $11.2M | $11.8M | $12.8M | $12.1M | $11.7M |
| Cost of revenue | $1.0M | $3.2M | $4.9M | $6.7M | $12.2M | $9.4M | $9.5M | $9.0M |
| Gross profit | $3.2M | $2.5M | $4.4M | $4.5M | −$381.0K | $3.3M | $2.5M | $2.7M |
| Gross margin | 76.0% | 43.8% | 47.3% | 39.9% | -3.2% | 25.9% | 21.1% | 23.1% |
| R&D | $22.3M | $27.6M | $25.3M | $21.3M | $21.9M | $26.9M | $25.4M | $16.7M |
| Operating income | −$64.2M | −$80.4M | −$72.8M | −$63.7M | −$71.6M | −$62.8M | −$54.0M | −$35.3M |
| EBITDA | −$61.3M | −$75.4M | −$67.6M | −$59.7M | −$59.6M | −$55.8M | −$49.8M | −$33.6M |
| Net income | −$62.9M | −$88.3M | −$84.3M | −$78.2M | −$77.7M | −$62.5M | −$61.6M | −$50.0M |
| Net margin | -1505.4% | -1557.8% | -906.8% | -700.5% | -659.5% | -490.1% | -511.0% | -427.8% |
| EPS (diluted) | -11.63 | -16.21 | -15.47 | -13.96 | -12.59 | -7.61 | -4.94 | -2.15 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $22M | $-0.36 | $-0.36–$-0.36 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds AXDX.
No tracked institution reports a position in AXDX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-07-12 | 1-for-10reverse |
No one on the platform has traded AXDX yet.
| $24M |
| — |
| HTGMQHTG Molecular Diagnostics, Inc. | $0.00 | +0.00% | $221 | — |
| IMPLImpel Pharmaceuticals Inc. | $0.04 | -27.27% | $956000 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 8.5× historical median P/S.
Fair value ≈ $10.42 · price $0.03 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AXDX Amazing what happened here. Turns out that there was demand for Wave in that Bruker bought it from Indaba. Micro Guy was wrong. But Micro Guy was right in that shareholders got screwed. No price mentioned
View on StockTwits ↗$AXDX and all assets sold to Bruker today under new company, AST Revolution
View on StockTwits ↗$AXDX lost my shirt on this one. Hard to think that there is 0 value in the technology. Maybe someone will pick up the pieces and turn it into something that has some utility. Maybe a smartwatch or something lol. All the signs of failure were there. I was just blinded by the fantasy of what could be. Meh moving on.....
View on StockTwits ↗$AXDX Google Accelerate Diagnostics Bankruptcy and you will find a site called "Stretto" that has all of the filings. Fascinating reading. Incompetence beyond incompetence. And the dumbest was likely Indaba who put money into this as a DIP and put out a stalking horse bid. Bottom line? MicroGuy was right and I was wrong. THere was and is no demand for a combined diagnostic blood and isoaltes. The irony? BDX liked Pheno! And Indaba discontinued it! Had AXDX sold to BDX instead of holding out for Wave it's likely that Pheno would be part of BDX's toolbox and AXDX would have avoided bankruptcy. By the way? I think this is going to go Chapter 7.
View on StockTwits ↗$AXDX another example of a stock that the naked shorting killed-one less stock for them to trade-they cut off their nose to spite their face. The time is coming where this will stop. Reaching new highs again, the major indices will not be a buy but the beaten down micro caps will be.
View on StockTwits ↗$DMN $AXDX went up 5xs in AH the day before the pink sheets. The MMs will squeeze this throughout the day-no way will they not make $$$ off the new shorts.
View on StockTwits ↗$DMN $AXDX Not even close in comparison AXDX 25 million FLOAT DMN 2.4 BILLION FLOAT
View on StockTwits ↗$DMN $AXDX run up from 0.03 to 0.15 just before delist....just saying.
View on StockTwits ↗$AXDX RIP Accelerate. At least the conclusion makes sense, unlike everything that preceded it, including tons of pointless investments. If only the investors took a bit of time and reached out to the actual users - clinical laboratories.
View on StockTwits ↗@Basherrr there are more bag holders shorts at this point than longs. That is the difference right now-that is why it started going back up and they halted it. But like $AXDX and $AFMD , it will move up at some point-most longs sold.
View on StockTwits ↗$AXDX flip the scrip on them, Stock is Still Strong ! even though I lost I can turn this into a WIN!!
View on StockTwits ↗$AXDX gone up just can't sell it load of shit😡
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.